Evaluation of the EMulate Therapeutics Voyager’s ultra-low radiofrequency energy in murine model of glioblastoma

" An experimental medical device, the Voyager leverages the power of localized, ultra-low (0-22kHz) radio frequency energy (ulRFE) to inhibit cancers including GBM (Barkhoudarian et al. 2023; Cobbs et al. 2019; Murphy et al. 2019; Ulasov et al. 2017). At the heart of this technology are unique ulRFE signals, termed cognates. These cognates owe their genesis to a sophisticated, ultrasensitive magnetometer, designed to detect and record the subtle alterations in magnetic fields generated by solvated molecules (Cobbs et al. 2019; Murphy et al. 2019; Ulasov et al. 2017; Butters et al. 2014)." {Credits 1}

" Diving deeper into the spectrum of cognates, the ulRFE cognate A1A, inspired by the dynamics of paclitaxel, is hypothesized to hinder cell division and proliferation (Butters et al. 2014). On the other hand, the ulRFE cognate A2, conceptualized from murine siRNA sequences, bears the potential to suppress CTLA-4 and PD-1 expression, pivotal checkpoints in the immune response (Barber et al. 2006; Pedicord et al. 2011)." {Credits 1}

" The primary aim of these studies was to determine if the Voyager has a measurable biological effect when used in xenograft and syngeneic models of GBM. Results from the studies strongly suggest that the Voyager can effectively target glioma cells in in vivo experiments." {Credits 1}

{Credits 1} 🎪 Mukthavaram, R., Jiang, P., Pastorino, S. et al. Evaluation of the EMulate Therapeutics Voyager’s ultra-low radiofrequency energy in murine model of glioblastoma. Bioelectron Med 10, 10 (2024). https://doi.org/10.1186/s42234-024-00143-8. © 2024 The Author(s). This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 License.